Serono Licenses Aurora Kinase Inhibitors from Rigel
By Business Review Editor
Pharma Deals Review: Vol 2005 Issue 66 (Table of Contents)
Published: 5 Dec-2005
DOI: 10.3833/pdr.v2005.i66.588 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Rigel Pharmaceuticals and Serono International entered into licensing agreement to develop and commercialize Rigel’s aurora kinase inhibitor, R763 for treating cancer...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018